Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
Objective: To evaluate the efficacy and safety of the continuing immunotherapy as subsequent therapy in extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after initial immunotherapy. Methods: A retrospective analysis was conducted on patients with ES-SCLC who experienced...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003759 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591858018025472 |
|---|---|
| author | Jianfeng Peng Xueying Zhai Xiaomei Liu Zhaoqin Huang Yimeng Wang Peizhu Wu Ran Gao Xiangjiao Meng |
| author_facet | Jianfeng Peng Xueying Zhai Xiaomei Liu Zhaoqin Huang Yimeng Wang Peizhu Wu Ran Gao Xiangjiao Meng |
| author_sort | Jianfeng Peng |
| collection | DOAJ |
| description | Objective: To evaluate the efficacy and safety of the continuing immunotherapy as subsequent therapy in extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after initial immunotherapy. Methods: A retrospective analysis was conducted on patients with ES-SCLC who experienced disease progression after receiving programmed cell death ligand 1 (PD-L1) inhibitors combined with standard chemotherapy as first-line treatment at three sites in China. Patients were divided into two groups according to whether to continue second-line immunotherapy. Results: In a cohort of 150 ES-SCLC patients evaluated post-progression following first-line PD-L1 inhibitors, second-line treatment regimens varied: 86 patients received immunotherapy beyond progression (IBP) and 64 did not proceed to second-line immunotherapy (non-IBP). IBP significantly increased both disease control rates (DCR, 68.6% vs. 32.8%, p<0.001) and overall response rate (ORR, 33.7% vs. 15.6%, p=0.012) and extended median progression-free survival (PFS, 4.1 vs. 2.4 months, HR=0.46, p<0.001) when compared with non-IBP group. The median overall survival (OS) in the IBP group was also longer than that in the non-IBP group (11.2 months vs. 9.0 months, HR=0.68, 95%CI 0.47-0.98, p=0.042). Subgroup analyses revealed a significant survival advantage with IBP treatment in patients presenting with baseline liver metastases, less than three metastatic organs, and those who were nonsmokers. Conclusions: In patients with ES-SCLC who received first-line PD-L1 inhibitors, continuing IBP extended second-line survival without increasing adverse events (AEs). A more pronounced OS benefit with IBP was noted within specific patient subgroups. |
| format | Article |
| id | doaj-art-9a1e41c376714afbb90eedba0f7bf6a5 |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-9a1e41c376714afbb90eedba0f7bf6a52025-01-22T05:41:28ZengElsevierTranslational Oncology1936-52332025-02-0152102249Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progressionJianfeng Peng0Xueying Zhai1Xiaomei Liu2Zhaoqin Huang3Yimeng Wang4Peizhu Wu5Ran Gao6Xiangjiao Meng7Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Oncology, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, ChinaDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Department of Shandong Provincial Key Laboratory of Precision Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; Corresponding author: Xiangjiao Meng, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jiyan Road 440, Jinan 250117, Shandong, ChinaObjective: To evaluate the efficacy and safety of the continuing immunotherapy as subsequent therapy in extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after initial immunotherapy. Methods: A retrospective analysis was conducted on patients with ES-SCLC who experienced disease progression after receiving programmed cell death ligand 1 (PD-L1) inhibitors combined with standard chemotherapy as first-line treatment at three sites in China. Patients were divided into two groups according to whether to continue second-line immunotherapy. Results: In a cohort of 150 ES-SCLC patients evaluated post-progression following first-line PD-L1 inhibitors, second-line treatment regimens varied: 86 patients received immunotherapy beyond progression (IBP) and 64 did not proceed to second-line immunotherapy (non-IBP). IBP significantly increased both disease control rates (DCR, 68.6% vs. 32.8%, p<0.001) and overall response rate (ORR, 33.7% vs. 15.6%, p=0.012) and extended median progression-free survival (PFS, 4.1 vs. 2.4 months, HR=0.46, p<0.001) when compared with non-IBP group. The median overall survival (OS) in the IBP group was also longer than that in the non-IBP group (11.2 months vs. 9.0 months, HR=0.68, 95%CI 0.47-0.98, p=0.042). Subgroup analyses revealed a significant survival advantage with IBP treatment in patients presenting with baseline liver metastases, less than three metastatic organs, and those who were nonsmokers. Conclusions: In patients with ES-SCLC who received first-line PD-L1 inhibitors, continuing IBP extended second-line survival without increasing adverse events (AEs). A more pronounced OS benefit with IBP was noted within specific patient subgroups.http://www.sciencedirect.com/science/article/pii/S1936523324003759extensive-stage small cell lung cancerimmunotherapyimmunotherapy beyond progressionsecond-line treatmentsurvival |
| spellingShingle | Jianfeng Peng Xueying Zhai Xiaomei Liu Zhaoqin Huang Yimeng Wang Peizhu Wu Ran Gao Xiangjiao Meng Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression Translational Oncology extensive-stage small cell lung cancer immunotherapy immunotherapy beyond progression second-line treatment survival |
| title | Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression |
| title_full | Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression |
| title_fullStr | Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression |
| title_full_unstemmed | Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression |
| title_short | Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression |
| title_sort | beyond first line therapy efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after pd l1 inhibitor progression |
| topic | extensive-stage small cell lung cancer immunotherapy immunotherapy beyond progression second-line treatment survival |
| url | http://www.sciencedirect.com/science/article/pii/S1936523324003759 |
| work_keys_str_mv | AT jianfengpeng beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT xueyingzhai beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT xiaomeiliu beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT zhaoqinhuang beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT yimengwang beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT peizhuwu beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT rangao beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression AT xiangjiaomeng beyondfirstlinetherapyefficacyandsafetyoutcomesofcontinuingimmunotherapyinextensivestagesmallcelllungcancerafterpdl1inhibitorprogression |